Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- $1.11 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ainos Inc. had its IPO on 2022-08-09 under the ticker symbol AIMDW.
The company operates in the Healthcare sector and Biotechnology industry. Ainos Inc. has a staff strength of 34 employees.
Shares of Ainos Inc. opened at $0.31 at the start of the last trading session i.e. 2023-03-29.
The stocks traded within a range of $0.31 - $0.31, and closed at $0.31.
This is a 0% increase from the previous day's closing price.
A total volume of 100 shares were traded at the close of the day’s session.
In the last one week, shares of Ainos Inc. have slipped by -29.72%.
Ainos Inc.'s Key Ratios
Ainos Inc. has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Ainos Inc.’s revenue was $1.11 million with a gross profit of $0 and an EBITDA of $-2737697. The EBITDA ratio measures Ainos Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ainos Inc.’s operating margin was -596.99% while its return on assets stood at -13.61% with a return of equity of -55%.
In Q3, Ainos Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 213.6%.
Ainos Inc.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ainos Inc.’s profitability.
Ainos Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Ainos Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $39.08 million
- Total Liabilities
- $2.64 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ainos Inc. ended 2023 with $39.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.08 million while shareholder equity stood at $36.43 million.
Ainos Inc. ended 2023 with $0 in deferred long-term liabilities, $2.64 million in other current liabilities, 194783.00 in common stock, $-21984598.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.42 million and cash and short-term investments were $2.42 million. The company’s total short-term debt was $1,260,526 while long-term debt stood at $0.
Ainos Inc.’s total current assets stands at $3.67 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $400198.00 compared to accounts payable of $0 and inventory worth $698295.00.
In 2023, Ainos Inc.'s operating cash flow was $0 while its capital expenditure stood at $245235.
Comparatively, Ainos Inc. paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ainos Inc. stock is currently trading at $0.31 per share. It touched a 52-week high of $0.892 and a 52-week low of $0.892. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.32 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Ainos Inc.
Similar Industry Stocks (Biotechnology)
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.